|
|
|
|
The pore-forming toxin β hemolysin/cytolysin triggers p38 MAPK-dependent IL-10 production in macrophages and inhibits innate immunity
|
|
|
|
|
|
|
|
نویسنده
|
bebien m. ,hensler m.e. ,davanture s. ,hsu l.-c. ,karin m. ,park j.m. ,alexopoulou l. ,liu g.y. ,nizet v. ,lawrence t.
|
|
منبع
|
plos pathogens - 2012 - دوره : 8 - شماره : 7 - صفحه:29
|
|
چکیده
|
Group b streptococcus (gbs) is a leading cause of invasive bacterial infections in human newborns and immune-compromised adults. the pore-forming toxin (pft) β hemolysin/cytolysin (βh/c) is a major virulence factor for gbs,which is generally attributed to its cytolytic functions. here we show βh/c has immunomodulatory properties on macrophages at sub-lytic concentrations. βh/c-mediated activation of p38 mapk drives expression of the anti-inflammatory and immunosuppressive cytokine il-10,and inhibits both il-12 and nos2 expression in gbs-infected macrophages,which are critical factors in host defense. isogenic mutant bacteria lacking βh/c fail to activate p38-mediated il-10 production in macrophages and promote increased il-12 and nos2 expression. furthermore,targeted deletion of p38 in macrophages increases resistance to invasive gbs infection in mice,associated with impaired il-10 induction and increased il-12 production in vivo. these data suggest p38 mapk activation by βh/c contributes to evasion of host defense through induction of il-10 expression and inhibition of macrophage activation,a new mechanism of action for a pft and a novel anti-inflammatory role for p38 in the pathogenesis of invasive bacterial infection. our studies suggest p38 mapk may represent a new therapeutic target to blunt virulence and improve clinical outcome of invasive gbs infection. © 2012 bebien et al.
|
|
|
|
|
آدرس
|
centre d'immunologie de marseille-luminy (ciml),aix-marseille university,um2,marseille,france,institut national de la santé et de la recherche médicale (inserm),u1104,marseille,france,centre national de la recherche scientifique (cnrs),umr7280,marseille, France, department of pediatrics and skaggs school of pharmacy and pharmaceutical sciences,university of california san diego,school of medicine,la jolla,ca, United States, centre d'immunologie de marseille-luminy (ciml),aix-marseille university,um2,marseille,france,institut national de la santé et de la recherche médicale (inserm),u1104,marseille,france,centre national de la recherche scientifique (cnrs),umr7280,marseille, France, department of pharmacology,university of california san diego,school of medicine,la jolla,ca,united states,institute of molecular medicine,college of medicine,national taiwan university,taipei, Taiwan, department of pharmacology,university of california san diego,school of medicine,la jolla,ca, United States, cutaneous biology research center,massachusetts general hospital,charlestown,ma, United States, centre d'immunologie de marseille-luminy (ciml),aix-marseille university,um2,marseille,france,institut national de la santé et de la recherche médicale (inserm),u1104,marseille,france,centre national de la recherche scientifique (cnrs),umr7280,marseille, France, immunobiology institute,cedars-sinai medical center,university of california los angeles,school of medicine,los angeles,ca, United States, department of pediatrics and skaggs school of pharmacy and pharmaceutical sciences,university of california san diego,school of medicine,la jolla,ca, United States, centre d'immunologie de marseille-luminy (ciml),aix-marseille university,um2,marseille,france,institut national de la santé et de la recherche médicale (inserm),u1104,marseille,france,centre national de la recherche scientifique (cnrs),umr7280,marseille, France
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|